Page 304 - Haematologica April 2020

F. Baron et al.
References
1. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the SociÇtÇ Franáaise de Greffe de Moelle. J Clin Oncol. 2000;18(3):537-571.
2. Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002; 100(2):415-419.
3. Stem Cell Trialists' Collaborative G. Allogeneic peripheral blood stem-cell com- pared with bone marrow transplantation in the management of hematologic malignan- cies: an individual patient data meta-analy- sis of nine randomized trials. J Clin Oncol. 2005;23(22):5074-5087.
4. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
5. Lee SJ, Logan B, Westervelt P, et al. Comparison of patient-reported outcomes in 5-Year survivors who received bone mar- row vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2016;2(12):1583-1589.
6. Battipaglia G, Ruggeri A, Labopin M, et al. Refined graft-versus-host disease/relapse- free survival in transplant from HLA-identi- cal related or unrelated donors in acute myeloid leukemia. Bone Marrow Transplant. 2018;53(10):1295-1303.
7. Kroger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43-53.
8. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft- versus-host disease, chronic lung dysfunc- tion, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560-565.
9. Walker I, Schultz KR, Toze CL, et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unre- lated donor transplantation: CBMTG 0801, a randomized, controlled trial. Blood. 2014; 124(21):38.
10. Finke J, Schmoor C, Bethge WA, et al. Long-term outcomes after standard graft-
versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised con- trolled trial. Lancet Haematol. 2017; 4(6):e293-e301.
11. Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, Phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft- versus-host disease-free survival in patients undergoing HLA-matched unrelated mye- loablative hematopoietic cell transplanta- tion. J Clin Oncol. 2017;35(36):4003-4011.
12. Baron F, Mohty M, Blaise D, et al. Anti-thy- mocyte globulin as graft-versus-host dis- ease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(2):224-234.
13. Rubio MT, D'Aveni-Piney M, Labopin M, et al. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell trans- plantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regi- men: a report from the EBMT Acute Leukemia Working Party. J Hematol Oncol. 2017;10(1):31.
14. Baron F, Ruggeri A, Beohou E, et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukemia: a report from Eurocord and the ALWP of the EBMT. J Intern Med. 2018; 283(2):178-189.
15. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
16. Baron F, Ruggeri A, Beohou E, et al. RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016; 7(28):43027-43038.
17. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-611.
18. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;
18(12):1489-1500.
19. Baron F, Labopin M, Ruggeri A, et al.
Impact of donor type in patients with AML given allogeneic hematopoietic cell trans- plantation after low-dose TBI-based regi- men. Clin Cancer Res. 2018; 24(12):2794- 2803.
20. Potdar RR, Gupta S, Giebel S, et al. Current status and Perspectives of irradiation-based conditioning regimens for patients with acute leukemia undergoing hematopoietic stem cell transplantation. Clin Hematol International. 2019;1(1):19-27.
21. Baron F, Labopin M, Peniket A, et al. Reduced-intensity conditioning with flu- darabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121(7):1048- 1055.
22. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, and the Seattle Marrow Transplant T. Antileukemic effect of chron- ic graft-versus-host disease. Contribution to improved survival after allogeneic mar- row transplantation. N Engl J Med. 1981; 304(25):1529-1533.
23. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23(9):1993-2003.
24. Baron F, Labopin M, Niederwieser D, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplanta- tion. Leukemia. 2012;26(12):2462-2468.
25. Baron F, Labopin M, Blaise D, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity con- ditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(3):389-396.
26. Nagler A, Labopin M, Dholaria B, et al. Impact of antithymocyte globulin on out- comes of allogeneic hematopoietic cell transplantation with TBI. Blood Adv. 2019; 3(13):1950-1960.
27. Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allo- geneic hematopoietic cell transplantation. Blood. 2015;125(8):1333-1338.
1146
haematologica | 2020; 105(4)